

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM573355

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Oxford Finance LLC		04/10/2020	Limited Liability Company: DELAWARE
RECEIVING PARTY DATA			
Name:	Tocagen, Inc.		
Street Address:	4242 Campus Point Court		
Internal Address:	Suite 600		
City:	San Diego		
State/Country:	CALIFORNIA		
Postal Code:	92121		
Entity Type:	Corporation: DELAWARE		
PROPERTY NUMBERS Total: 5			
Property Type	Number	Word Mark	
Serial Number:	88118013	SEEKFUZA	
Serial Number:	88117990	AMISYNKA	
Serial Number:	88117965	VOCIRRVA	
Serial Number:	88117944	TOCFUSO	
Serial Number:	88117896	TOKIRYK	
CORRESPONDENCE DATA			
Fax Number:	8584589986		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	858-458-3607		
Email:	lucille.begalla@bbiplaw.com		
Correspondent Name:	Joseph R. Baker, Jr.		
Address Line 1:	4370 La Jolla Village Drive		
Address Line 2:	Suite 303		
Address Line 4:	San Diego, CALIFORNIA 92122		
NAME OF SUBMITTER:	Joseph R. Baker, Jr.		
SIGNATURE:	/Joseph R. Baker, Jr./		
DATE SIGNED:	04/23/2020		

OP \$140.00 88118013

Total Attachments: 8

source=Security_Interest_Release#page1.tif

source=Security_Interest_Release#page2.tif

source=Security_Interest_Release#page3.tif

source=Security_Interest_Release#page4.tif

source=Security_Interest_Release#page5.tif

source=Security_Interest_Release#page6.tif

source=Security_Interest_Release#page7.tif

source=Security_Interest_Release#page8.tif

RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY

This **RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY** (this "Release") dated as of April 10, 2020, is made by **OXFORD FINANCE LLC**, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 ("**Oxford**"), as collateral agent (in such capacity, "**Collateral Agent**"), the Lenders listed on Schedule 1.1 of the Loan Agreement (defined below) or otherwise a party thereto from time to time including Oxford in its capacity as a Lender and **SILICON VALLEY BANK**, a California corporation with an office located at 3003 Tasman Drive, Santa Clara, CA 95054 ("**Bank**" or "**SVB**") (each a "**Lender**" and collectively, the "**Lenders**"), in favor of TOGAGEN, INC., a Delaware corporation ("**Grantor**").

WHEREAS, pursuant to that certain Intellectual Property Security Agreement dated as of October 31, 2019, by and between Grantor and Collateral Agent (the "**IPSA**"), and Amended and Restated Loan and Security Agreement dated as of May 18, 2018 (as amended, supplemented or otherwise modified from time to time, including, but without limitation, by that certain First Amendment to Amended and Restated Loan and Security Agreement dated as of August 3, 2019, and that certain Second Amendment to Amended and Restated Loan and Security Agreement dated as of October 31, 2019, the "Loan Agreement"), by and among Grantor, Collateral Agent and Lenders, Grantor granted to Collateral Agent a continuing security interest in all of Grantor's right, title, and interest in and to certain intellectual property assets, including, without limitation, the patents and patent applications set forth on Exhibit A attached hereto (the "Patent Collateral"), and the trademark registrations and applications set forth on Exhibit B attached hereto (the "Trademark Collateral");

WHEREAS, the IPSA was recorded with the United States Patent and Trademark Office on November 4, 2019, at Reel/Frame 050909/0548 with respect to the Patent Collateral and at Reel/Frame 6787/0031 with respect to the Trademark Collateral; and

WHEREAS, any and all secured obligations as defined by the Loan Agreement have been satisfied, and the requirements of the Loan Agreement for discharge of the liens in the Patent Collateral and Trademark Collateral have been satisfied.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Collateral Agent hereby terminate the IPSA, and hereby terminate, cancel, and release any and all security interests it has against the Patent Collateral, and Trademark Collateral thereunder.

The parties hereto agree that, at any time and from time to time upon written request of the other party, each party will execute and deliver such documents and do such further acts as may be reasonably requested by the other party in order to effect the purpose of this Release.

[SIGNATURES ON NEXT PAGE]

IN WITNESS WHEREOF, Lenders have caused this Release to be executed by their duly authorized representative as of the date hereof.

COLLATERAL AGENT:

OXFORD FINANCE LLC, AS COLLATERAL AGENT

By: 

Name: Colette H. Featherly

Title: Senior Vice President

[Signature Page – Release of Security Interest in Intellectual Property]

SCHEDULE A

Patent Collateral

No.	Description	Application Number	Registration Number
1.	Retroviral Vector Having Immune-Stimulating Activity	15/127,388 (09/19/2016)	
2.	Gene Therapy Vectors and Cytosine Deaminases		8,722,867 (05/13/2014)
3.	Formulations of 5-Fluorocytosine and Uses Thereof		9,320,738 (04/26/2016)
4.	Cancer Combination Therapy and Recombinant Vectors		9,642,921 (05/09/2017)
5.	Compositions Comprising Gamma Retrovirus Vectors and Methods of Treating Proliferative Disorders		9,669,049 (06/06/2017)
6.	Recombinant Vectors		9,732,326 (08/15/2017)
7.	Formulations of 5-Fluorocytosine and Uses Thereof		9,889,133 (02/13/2018)

42019099v4

No.	Description	Application Number	Registration Number
8.	Producer Cells for Replication Competent Retroviral Vectors		10,316,333 (06/11/2019)
9.	Cancer Treatment with Recombinant Vector	13/638,490 (01/16/2013)	
10.	Antisera Assays for MLV Related Viruses in Humans and Other Mammals	13/882,713 (03/03/2014)	
11.	Gene Therapy Vectors and Cytosine Deaminases		10,035,983 (07/31/2018)
12.	Retroviral Vector with Mini-Promoter Cassette	14/438,564 (04/24/2015)	
13.	Immunosuppressive Components Associated with Retroviral Replicating Vectors	14/897,847 (12/11/2015)	
14.	Recombinant Vector with Stabilizing A-Loop	15/016,201 (02/04/2016)	

No.	Description	Application Number	Registration Number
15.	Enhanced Cancer Treatment and Monitoring Using Recombinant Vectors	15/611,722 (06/01/2017)	
16.	Recombinant Vectors		10,407,666 (09/10/2019)
17.	Recombinant Vectors		8,829,173 (09/09/2014)
18.	Retrovirus Detection		9,663,834 (05/30/2017)
19.	Recombinant Vectors Comprising 2A Peptide	15/757,292 (03/02/2018)	
20.	Formulations of 5-Fluorocytosine and Uses Thereof		10,449,194 (10/22/2019)
21.	Gene Therapy and Cytosine Deaminases	16/044,472 (07/24/2018)	

No.	Description	Application Number	Registration Number
22.	Gene Expression Patterns to Predict Responsiveness to Virotherapy in Cancer Indications	PCT US2016060725 (11/04/2016)	
23.	Recombinant Vectors Comprising 2A Peptide	PCT US2016049947 (09/01/2016)	
24.	A Retroviral Vector Having Immune-Stimulating Activity	PCT US2015022512 (03/25/2015)	
25.	Recombinant Vector with Optimized A-Bulge	PCT US2014049831 (08/05/2014)	
26.	Immunosuppressive Components Associated with Retroviral Replicating Vectors	PCT US2014042444 (06/15/2014)	
27.	Retroviral Vector with Mini-Promoter Cassette	PCT US2013066709 (10/24/2013)	
28.	Antisera Assays for MLV Related Viruses in Humans and Other Mammals	PCT US2011058457 (10/28/2011)	

No.	Description	Application Number	Registration Number
29.	Enhanced Cancer Treatment and Monitoring Using Recombinant Vectors	PCT US2011058595 (10/31/2011)	
30.	Retrovirus Detection	PCT US2011044296 (07/16/2011)	
31.	Cancer Treatment with Recombinant Vector	PCT US2011030402 (03/29/2011)	
32.	Producer Cells for Replication Competent Retroviral Vectors	PCT US2010038996 (06/17/2010)	
33.	Gene Therapy Vectors and Cytosine Deaminases	PCT US2009058510 (09/26/2009)	
34.	Recombinant Vectors	PCT US2009058512 (09/26/2009)	
35.	Formulations of 5-Fluorocytosine and Uses Thereof	PCT US2009049322 (06/30/2009)	

42019099v4

SCHEDULE B

Trademark Collateral

Trademarks

No.	Description	Serial Number	Registration Number
1.	SEEKFUZA	88/118,013 (09/14/2018)	
2.	AMISYNKA	88/117,990 (09/14/2018)	
3.	VOCIRVA	88/117,965 (09/14/2018)	
4.	TOCFUSO	88/117,944 (09/14/2018)	
5.	TOKIRYK	88/117,896 (09/14/2018)	

42019099v4